Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Begoña Calvo

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Drug Safety|December 17, 2013
Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars"Begoña Calvo
Drug Safety|November 6, 2013
EU's new pharmacovigilance legislation: considerations for biosimilarsBegoña Calvo, Leyre Zuñiga
Pharmacoepidemiology and Drug Safety|June 29, 2010
Biosimilars: pharmacovigilance and risk managementLeyre Zuñiga, Begoña Calvo
Regulatory Toxicology and Pharmacology : RTP|November 21, 2009
Biosimilars approval processLeyre Zuñiga, Begoña Calvo
Current Medicinal Chemistry|September 18, 2012
Therapeutic monoclonal antibodies: strategies and challenges for biosimilars developmentBegoña Calvo, Leyre Zuñiga
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 4, 2012
The US approach to biosimilars: the long-awaited FDA approval pathwayBegoña Calvo, Leyre Zuñiga
Trends in Biotechnology|May 27, 2009
Regulatory aspects of biosimilars in EuropeLeyre Zuñiga, Begoña Calvo
Current Pharmaceutical Biotechnology|November 27, 2009
Global vision about the biological medicinal products: biosimilars (April, 2009)Leyre Zuñiga, Begoña Calvo
Revista De Enfermeria (Barcelona, Spain)|December 22, 2015
[ETHICAL CONFLICTS AT THE END OF LIFE FROM NURSE PERCEPTION]Begoña Calvo Rodríguez, Ignacio Berdial Cabal
The Annals of Pharmacotherapy|April 9, 2002
Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapyBernardino Roca, Begoña Calvo, Rafael Monferrer
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Drug Safety|December 17, 2013
Author's reply to Borg et al. Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars"Begoña Calvo
Drug Safety|November 6, 2013
EU's new pharmacovigilance legislation: considerations for biosimilarsBegoña Calvo, Leyre Zuñiga
Pharmacoepidemiology and Drug Safety|June 29, 2010
Biosimilars: pharmacovigilance and risk managementLeyre Zuñiga, Begoña Calvo
Regulatory Toxicology and Pharmacology : RTP|November 21, 2009
Biosimilars approval processLeyre Zuñiga, Begoña Calvo
Current Medicinal Chemistry|September 18, 2012
Therapeutic monoclonal antibodies: strategies and challenges for biosimilars developmentBegoña Calvo, Leyre Zuñiga
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 4, 2012
The US approach to biosimilars: the long-awaited FDA approval pathwayBegoña Calvo, Leyre Zuñiga
Trends in Biotechnology|May 27, 2009
Regulatory aspects of biosimilars in EuropeLeyre Zuñiga, Begoña Calvo
Current Pharmaceutical Biotechnology|November 27, 2009
Global vision about the biological medicinal products: biosimilars (April, 2009)Leyre Zuñiga, Begoña Calvo
Revista De Enfermeria (Barcelona, Spain)|December 22, 2015
[ETHICAL CONFLICTS AT THE END OF LIFE FROM NURSE PERCEPTION]Begoña Calvo Rodríguez, Ignacio Berdial Cabal
The Annals of Pharmacotherapy|April 9, 2002
Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapyBernardino Roca, Begoña Calvo, Rafael Monferrer
Pageof 9